Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium longum KB35 is a specific probiotic bacterial strain developed by Kibun Foods Inc. for the management of hyperuricemia and gout. The strain is characterized by its high purine-degrading activity, specifically targeting purine nucleosides such as inosine and guanosine within the intestinal lumen. By breaking down these substrates before they can be absorbed into the systemic circulation, KB35 reduces the availability of precursors for hepatic uric acid synthesis, thereby lowering serum uric acid levels. Clinical investigations in Japan have evaluated KB35 as a live biotherapeutic product or functional food ingredient to assist in the control of asymptomatic hyperuricemia and prevent the onset of gouty arthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bifidobacterium longum KB35.